TY  - GEN
AU  - Huang,Shile
AU  - Huang,Shile
TI  - mTOR Signaling in Metabolism and Cancer
SN  - books978-3-03943-554-8
PY  - 2020///
CY  - Basel, Switzerland
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Medicine
KW  - bicssc
KW  - mTOR
KW  - histone deacetylase
KW  - prostate cancer
KW  - integrins
KW  - adhesion
KW  - invasion
KW  - cell metabolism
KW  - T cells
KW  - Foxp3
KW  - Acute Lymphoblastic leukemia
KW  - targeted therapy
KW  - metabolism
KW  - cell signalling
KW  - mTOR signalling
KW  - head and neck cancer
KW  - mutant genes
KW  - biomarkers
KW  - targeted therapies
KW  - clinical trials
KW  - cancers
KW  - inhibitors
KW  - photodynamic therapy
KW  - PI3K
KW  - Akt
KW  - skin cancers
KW  - phytochemicals
KW  - melanoma
KW  - basal cell carcinoma
KW  - squamous cell carcinoma
KW  - Merkel cell carcinoma
KW  - TNBC
KW  - eribulin
KW  - PI3K/AKT/mTOR
KW  - everolimus
KW  - combination
KW  - synergy
KW  - mTOR signaling
KW  - tissue regeneration
KW  - neuron
KW  - muscle
KW  - liver
KW  - intestine
KW  - hematologic malignancies
KW  - regulatory T cells
KW  - tumor
N1  - Open Access
N2  - The mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regulator for human physiological activity. Deregulated mTOR signaling is implicated in a variety of disorders, such as cancer, obesity, diabetes, and neurodegenerative diseases. The papers published in this Special Issue summarize the current understanding of the mTOR pathway and its role in the regulation of tissue regeneration, regulatory T cell differentiation and function, and different types of cancer including hematologic malignancies, skin, prostate, breast, and head and neck cancer. The findings highlight that targeting mTOR pathway is a promising strategy to fight against certain human diseases
UR  - https://mdpi.com/books/pdfview/book/3163
UR  - https://directory.doabooks.org/handle/20.500.12854/69370
ER  -